What does this video actually claim?
Dylan Gemelli's Instagram post makes several dramatic claims about low testosterone: that it severely degrades quality of life, can be fatal in "severe hypogonadal conditions," and that average testosterone levels are dropping while normal ranges are misleadingly broad.
He's promoting content alongside Dr. Eric Berg and positioning himself as someone who understands the "harsh realities" that others supposedly miss. The post uses medical terms like "hypogonadism" but doesn't cite any specific studies or data.
This is classic social media health content: vague enough to avoid specific scrutiny, scary enough to grab attention, and confident enough to sound authoritative.
Is low testosterone actually fatal?
Gemelli's claim about "severe hypogonadal conditions being fatal" is his most dramatic assertion, but the evidence doesn't support calling hypogonadism a life-threatening condition in any meaningful sense.
The Testosterone Trials (Snyder et al., NEJM, 2016) followed 790 men with testosterone levels below 275 ng/dL for one year. No deaths were attributed to low testosterone itself. Some observational studies like Shores et al. (Archives of Internal Medicine, 2006) found associations between very low testosterone (under 250 ng/dL) and increased mortality, but these men typically had multiple serious health conditions.
Calling hypogonadism "fatal" is misleading fear-mongering. Men with very low testosterone may have worse health outcomes, but that's different from testosterone deficiency being a cause of death.
Are testosterone levels really plummeting?
Here's where Gemelli gets something right, though he doesn't provide the actual numbers. Testosterone levels have declined over recent decades, and the data is pretty clear on this point.
Travison et al. (Journal of Clinical Endocrinology and Metabolism, 2007) found that total testosterone levels dropped by about 1% per year between 1987 and 2004 in American men, independent of aging. A Danish study (Andersson et al., Journal of Clinical Endocrinology and Metabolism, 2007) found similar declines: men born in 1958-1962 had testosterone levels 14% lower than men born in 1943-1947.
So yes, average testosterone has declined. Whether this represents a health crisis requiring widespread treatment is a different question entirely.
What about those "normal" ranges?
Gemelli suggests that current reference ranges for testosterone are too broad and that "acceptable" levels might actually be problematic. This complaint has some merit, though it's more nuanced than his post suggests.
Most labs use reference ranges of roughly 250-1100 ng/dL for total testosterone. The Endocrine Society (Bhasin et al., Journal of Clinical Endocrinology and Metabolism, 2018) recommends considering treatment for men with levels consistently below 300 ng/dL who have symptoms. But here's the problem: symptoms of low testosterone overlap heavily with depression, sleep disorders, and normal aging.
The Testosterone Trials found that men with levels between 200-350 ng/dL did see some improvements with treatment, particularly in sexual function and mood. But the effects were modest, and many men didn't respond at all.
What should you actually know about low testosterone?
Low testosterone is real, and it can affect quality of life for some men. But Gemelli's presentation makes it sound both more common and more dangerous than the evidence suggests.
If you have symptoms like persistent fatigue, low libido, or mood changes, getting tested makes sense. But you'll need at least two morning blood tests showing levels below 300 ng/dL before most reputable doctors will consider treatment. The symptoms need to be bothersome enough to justify potential risks like increased red blood cell count or cardiovascular effects.
Don't let social media influencers diagnose you based on vague symptoms and population-level statistics. The decision to start testosterone therapy should involve careful evaluation of your individual situation, not fear about being "fatal" or anxiety about population averages.